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CYSTEINE DELETED TACHYPLESIN
PEPTIDE ANALOGS AS
ANTI-CANCER AGENTS
Jaylen E. Taylor
Dr. Deborah Heyl-Clegg, Mentor
ABSTRACT
Adenocarcinoma is a common type of non-small cell
cancer that represents 80% of all diagnosed lung cancers. Typical treatment methods include surgery, radiation therapy, and
chemotherapy, or some combination of the three. Although radiation therapy and chemotherapy treatments are effective at killing
cancer cells, the side effects and symptoms associated with these
treatments can cause severe damage to the patient’s body and even
encourage some fatal illnesses, such as sepsis. Research has been
focused on the development of other methods of treatment that
would be less harmful or even non-harmful to patients. Antimicrobial peptides are known for their potential in modern antibiotics
to treat bacteria-caused illnesses. The antimicrobial peptide, cysteine deleted tachyplesin (CDT), demonstrates both antibacterial
as well as anticancer properties. To improve the development of
CDT into a possible treatment for adenocarcinoma of the lung,
analogs of the peptide CDT containing the hyaluronan binding
sequence are being synthesized and tested on the cell line A549,
with the hopes of improving their anticancer characteristics and to
understand better the mechanism that allows CDT and its analogs
to cause adenocarcinoma cell death.

INTRODUCTION
Adenocarcinoma
In 2016, the American Cancer Society issued a report
indicating that 526,510 men and women were living with lung
cancer, and a projected 224,390 additional people would be diagnosed before the end of that year. A year later, the 2017 report
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showed that lung cancer had become the second most diagnosed
type of cancer in the United States in both men and women. The
report estimated that 222,500 cases would be diagnosed before the
conclusion of 2017, and, of those patients, an estimated 155,870
would die due to complications from the illness (American Cancer
Society, 2017).
Adenocarcinoma of the lung is the most commonly diagnosed type of non-small cell lung cancer (American Thoracic Society 2014). Lung cancer can be divided into two sub-categories: small
cell cancer and non-small cell cancer. Adenocarcinoma of the lung is
a type of non-small cell cancer. The cancer forms in the outer tissues
of the lung from cells that are responsible for making mucus (The
Roche Group 2017). Most lung cancers are known to be asymptomatic until the late stages (III and IV; Miller et al. 2016). Adenocarcinoma of the lung is characterized as being a slow growing cancer,
however, with the usual diagnosis of the cancer being in stage IV at a
median age of 70 years old, recovery can be very difficult, even with
aggressive treatment (American Cancer Society 2016).
Lung cancer, specifically adenocarcinoma, is directly
linked to levels of environmental carcinogenic exposure (American Cancer Society 2017). Men and women who smoke are 25
times more likely to develop lung cancer (American Cancer Society 2017). Risk factors include smoking and exposure to radon
gas, asbestos, diesel exhaust, radiation, and air pollution (American Cancer Society 2017). In a Croatian study conducted in 2014
by Kukulj et al., the lung cancer treatments of 212 newly diagnosed patients were monitored. Of the 212 patients, 186 were
diagnosed with small cell lung cancer, and 89 of these patients
had adenocarcinoma of the lung. As per the trend reported by the
American Cancer Society, the study found that median age of diagnosis was 65 years old, and 157 of the 212 patients (74.1%)
had stage IV cancer. Of the patients who took part in the study,
182 were smokers (85.5%). The data on the patients involved in
this cohort study solidify the link between carcinogenic exposure,
such as long-term smoking habits, and adenocarcinoma of the
lung (Kukulj et al. 2014).
In a separate study conducted by Yang et al. from 1986 to
1998, approximately 38,000 women between the ages of 55 and
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69, living in Iowa, were monitored with the intent of linking the
risk factor of smoking to the development of lung cancer. This
research study followed the women for 13 years. Of the 38,006
women in this study, 34% were former or current smokers at the
beginning of the study. Of the entire cohort, 234 of the women
developed adenocarcinoma of the lung. Published in 2002, this
study also draws a very strong conclusion that smoking, current
or past, can increase the risk of developing adenocarcinoma of the
lung (Yang et al. 2002).
The treatment for adenocarcinoma is usually surgery, in
combination with chemotherapy (American Cancer Society 2017).
An efficient and safe treatment method that would both eradicate
the cancer and not harm the patient is highly sought after.

The Dangers of Chemotherapy
Chemotherapy is a well-known cancer treatment method. It is
known to be efficient in killing cancerous cells; however, this
treatment method is also very effective at killing the healthy tissue
and cells surrounding the cancer. According to the American Thoracic Society (2014), after a non-small cell lung cancer progresses to stage III, chemotherapy is a strongly considered treatment
method. Chemotherapy causes side effects that are degenerative
to the quality of life of the patient, including, but not limited to,
fatigue, hair loss, nausea and vomiting, anemia, increased risk of
infection, kidney damage, and nerve damage (American Thoracic
Society 2014). The most concerning risk from chemotherapy is
the possibility of infection, which could prove deadly. Chemotherapy kills the cancer cells in the body that grow quickly, but it
also kills the cells that naturally grow quickly, such as hair cells,
nail cells, and white blood cells (Centers for Disease Control and
Prevention [CDC] 2017). With low white blood cell counts, a
patient undergoing chemotherapy is susceptible to infection and
even sepsis (CDC 2017). The efficiency, effectiveness, and safety
of chemotherapy call into question whether chemotherapy should
remain one of the primary treatment methods for distinct types of
lung cancer, including adenocarcinoma. There has been exploration into other treatment methods, such as targeted therapy. The
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Figure 1. Visual comparison of the components of the cell membrane of a healthy
mammalian cell and a bacterial cell. Antimicrobial peptides have more interaction
with the negative bacterial cell membranes due to charge. The healthy mammalian cell
membrane is neutral (Riedl et al. 2011).

possibility of using antimicrobial peptides (AMPs) as a safe, efficient treatment specifically for adenocarcinoma would bring us
one step closer to understanding the cure for this type of cancer.

Antimicrobial Peptides
AMPs are found in plants, animals, and other organisms.
AMPs are characterized as both cationic and amphipathic (Schweizer 2009). Recent advances in research have encouraged the
use of AMPs as targeted therapy to combat especially resistant
bacterial strains. The success of these targeted therapies is consistent with interaction with the cell membrane. Antimicrobial
peptides that kill bacteria through membrane interaction alone are
more likely to kill bacteria without giving them a chance to become resistant (Riedl et al. 2011). To do this, the membrane of
the bacterial cell must be penetrated. Models summarizing how
activity may take place are based both on the known characteristics of the bacterial cell and the peptide. The significant differ-
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ence between the bacterial cells and the healthy mammalian cells
is found in the charge of the membrane. Both gram-positive and
gram-negative bacteria have an overall negatively charged membrane. Bacteria gain their charge due to the molecules found on
the outside of the membrane. Bacterial cells are anionic due to
the acidic phospholipids found on the membrane. Healthy mammalian cells, on the other hand, are overall neutral, due to the presence of both cationic and anionic phospholipids, giving them a
zwitterionic character. Figure 1 (above) shows the composition of
the membrane of the cancer cell and bacterial cell comparatively
(Riedl et al. 2011). Because of the similarity, the mechanism by
which the membrane disruption takes place and induces cell death
is also thought to be similar.

Potential Mechanisms
There are four commonly cited models that seek to summarize the permeation of the bacterial or cancer cell membrane.
One of the possible mechanisms of the antibacterial characteristic
of AMPs is the invasion of the bacterial membrane after contact
is made, causing cell lysis and eventually cell death. Proposed
mechanisms for the interaction that cause cell lysis are the barrelstave model, the toroidal model (also known as worm-hole), and
the carpet model. All are visually represented in Figure 2 (Giuliani
et al. 2008). The product of all the models is the creation of a pore
in the plasma membrane in the case of bacteria, or the cell membrane in the case of a mammalian cancer cell. In the barrel-stave
model, the peptide selectively attaches to the membrane due to
the attractive charges of the peptide (positive) and the membrane
(negative). Multiple molecules of the peptide group together to
create a channel, lined with peptide, within the membrane. The
hydrophobic region of the peptide faces out, towards the hydrophobic regions of the lipid bilayer (Brogden 2005). Similarly, in
the toroidal model, the peptide creates a pore, but the lipid bilayer curves around so that the hydrophilic heads are facing out
where the lipid bilayer meets the hydrophobic side of the peptide
(Brogden 2005). In the carpet model, the peptide forms a layer
over the membrane and breaks the membrane down, causing cell
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Figure 2. Three potential mechanisms for the interaction of antimicrobial peptides and
the cell membrane of bacteria cells or cancer cells. The diagram also depicts how the
peptide interacts considering the polarity of the peptide (Giuliani et al. 2008)

lysis (Brogden 2005). This is sometimes also referred to as the
"detergent model" because the peptide breaks downs the membrane like a detergent.

Tachyplesin-1
Tachyplesin-1 (TP-1) is a β-hairpin cationic antimicrobial peptide
isolated from the hemocyte debris of the Japanese horseshoe crab,
Tachypleus tridentatus (Nakamura et al. 1988). TP-1’s unaltered
sequence is 17 amino acids in length (see Figure 3; Nakamura
et al. 1988). Using the single character symbol for each amino
acid, the sequence is as follows: KWCRFRVCGICYRRCR. The
peptide has been found to exhibit antimicrobial properties. The
increasing resistance of bacterial strains to antibiotics has caused
an interest in antimicrobial peptides, such as TP-1, as a solution
(Edwards et al. 2017).
TP-1 exhibits membrane disruptive activity in both gramnegative and gram-positive bacteria as well as fungi (Edwards et
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al. 2017). Previous studies have shown that TP-1 caused rapid cell
death to E. coli and S. aureus. In a study conducted by Hong et
al. (2015), E. coli treated for 60 minutes with the peptide had a
survival rate of 27%, while S. aureus being treated for 30 minutes
had a 10% survival rate. The antimicrobial properties of TP-1 are
substantiated by its efficiency in killing bacterial strains, but how
exactly does this take place? In the same study, the peptide was
dyed with fluorescein isothiocyanate (FITC) and visualized with
laser confocal scanning microscopy to determine the process of
TP-1. Hong et al. (2015) wrote the following summarizing the
process of TP-1 causing cell death in E. coli and S. aureus:
FITC-labeled tachyplesin I (10 μg/mL) penetrated the cell membrane and accumulated in the cytoplasm immediately after being added to the E. coli and
S. aureus cell cultures. In E. coli, tachyplesin I later accumulated at the head of the cytoplasm and caused cell
body transformation and also accumulated at a hole in
the cytoplasm. In S. aureus, no cell membrane disruption was observed following treatment with 10 μg/mL of
tachyplesin I, the same phenomenon was also observed
following treatment with 20 g/mL of tachyplesin I . The
mode of action of tachyplesin I on E. coli was determined
to be dose-dependent. Membrane disruption was clearly
visible in E. coli after treatment with 20 g/mL of tachyplesin
I for 3 min and 40 g/mL in no time. These results indicate
that the primary target of tachyplesin I is the cell membrane and cytoplasm of E. coli and S. aureus and that it has
a different killing mechanism for each bacterium. (p. 71)
To determine which amino acid(s) were responsible for
the activity, analogs of the sequence were tested in a separate
study (Edwards et al. 2017). In each analog, each amino acid was
replaced with alanine, one at a time, and additional analogs were
made where a cysteine was replaced with alanine. The experiment
tested a total of 32 analogs. All of the peptide analogs, despite
their rearrangement, retained their cationic charge. By altering and
rearranging the sequence of some analogs, Edwards et al. (2017)
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found that they were able to increase and decrease the activity of the
peptide analogs relative to TP-1. The analogs with the highest efficiencies were tested for toxicity against human embryonic kidney
cells (HEK293) and human red blood cells (RBCs). Determining if
these analogs were harmful to healthy cells⎯causing cell lysis⎯is
a crucial step in determining whether the peptide could even be considered an option for human treatment methods. The experiment
found that, while the antimicrobial activity was efficient, the hemolytic activity was often too high to be considered a viable treatment
for humans, whereas when the concentration was decreased, there
was little to no activity (Edwards et al. 2017).
As anticancer agents, peptides with anticancer activity
also initially rely on membrane interactions to induce apoptosis
(Chen et al. 2001). Chen et al. (2001) studied the effects of RGDTachyplesin, where amino acids are added at the N-terminus, on
TSU prostate cancer cells. They found that the disruption of the
mitochondria causes the activation of an apoptotic cascade. Overall, this study demonstrated the ability of RGD-Tachyplesin to
inhibit tumor growth and damage the cell membranes of cancer
cells to induce apoptosis. To explore further the abilities of TP-1,
previous studies have focused on the effects on the cell cycle. A
study conducted by Li et al. (2003) analyzed the effects of TP-1
on the regulation of the cell cycle in human heptocarcinoma cells
(SMMC-7721). Their experiment demonstrated that TP-1 can arrest cells at the G0/G1 phase. P53 and p16 protein levels were
also found to be significantly lower in the heptocarcinoma cells
that had been treated with TP-1. The proteins p53 and p16 both
interact with tumor suppressor pathways (Beauséjour et al. 2003).
When these proteins are mutated, the affected cells are more susceptible to becoming cancerous (Figure 3).

Cysteine Deleted Tachyplesin (CDT)
Cysteine deleted tachyplesin (CDT) is the analog of TP-1
with the four cysteines completely removed from the sequence. In
doing this, the peptide is still β-hairpin in shape despite elimination of the disulfide bonds (Ramamoorthy et al. 2006). CDT is 13
amino acids in length with the following sequence: KWFRVYRGIYRRR. The activity of CDT was studied by Saravanan et al.
(2012), and the study concluded that the bacterial activity, like
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TP-1, is due to the selectivity for the negatively charged lipids.
CDT successfully neutralized the LPS and “disrupted the permeability barrier of the outer membrane” (Saravanan et al. 2012 p.
1613). CDT succeeds in other areas of efficiency where TP-1 was

Figure 3. Tachyplesin-1 amino acid sequence depicting β-hairpin structure
(Edwards et al. 2017).

lacking as well. By running a hemolysis assay comparing TP-1
and CDT, it was concluded that CDT did not cause cell lysis in
concentrations less than 200 μg/mL, while TP-1 caused 10% of
hemolysis at concentrations of 100 μg/mL and 25% at concentrations of 150 μg/mL (Ramamoorthy et al. 2006). This makes CDT
much more promising as a pharmaceutical, due to the improved
therapeutic index.
As an anticancer agent, CDT was found to interact with
heparan sulfate and chondroitin sulfate, anionic glycosaminogylcans found on the surface of the cancer cell membrane (Fadnes et
al. 2009). Fadnes et al. (2009) found that lymphoma cells were
less vulnerable to other cationic peptides (lactoferricin) if they expressed heparin sulfate on the cell surface. Their study concluded
that, although some negatively charged molecules help with selectivity, molecular components such as heparan sulfate and chondroitin sulfate on the membrane of a cancer cell can inhibit peptide activity as well (Fadnes et al. 2009).
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Wood et al. (2014) conducted a study of CDT and its analogs that analyzed the hemolytic activity as well as the antimicrobial effects of CDT with the removal of arginine residues from the
C-terminus, to determine how many were necessary for activity.
As arginine was systematically removed from the C-terminus, the
activity against E. coli and S. aureus increased, but only CDTdesRR resulted in virtually no hemolysis. The removal of a third
arginine residue caused a significant increase in hemolysis and a
decrease in antimicrobial activity. CDT required 67 μM to cause
less than 1% hemolysis where CDTdesRR required 650 mM to
have the same hemolytic effect (Figure 4). These findings are important because they qualify CDT as a possible therapeutic treatment for cancer; the hemolysis must be practically non-existent to
be considered safe. If CDT and its analogs had resulted in elevated
levels of hemolysis, then they would be dangerous and potentially
deadly to humans.
Evans et al. (2017) tested four separate peptides against
adenocarcinoma human alveolar basal epithelial cell line (A549),
E. coli and S. aureus; CDT, D-CDT (where all amino acids have
the D-configuration), reverse CDT (where the amino acid sequence was “backwards” relative to CDT), and reverse D-CDT.
Their findings showed that D-CDT was more selective for the
negatively charged cells than the other peptide analogs. In addition, D-CDT was also showed the most activity with the least
amount of hemolytic activity. D-CDT had an IC50 of 9.813 μM
against A549 lung cancer cells, the most efficient of the analog
they tested. D-CDT’s ability to exhibit cytotoxicity against the ad-

Figure 4. Molecular structure of CDT (pepbank.mgh.harvard.edu)
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enocarcinoma cells substantiates its classification as a peptide that
shows activity against microbial and cancer cells, but lacks activity against healthy mammalian cells.

The Hyaluronan Binding Sequence and Cancer
Hyaluronan (HA) was discovered in 1934 by Karl Meyer
and John Palmer. One member of a bigger system of molecules,
receptors, and synthases that allow cancer cells to interact with the
environment around them (Simoni et al. 2002), HA is a glycosaminoglycan made up of repeating units of D-glucuronic acid and
N-acetylglucosamine (see Figure 5 below; Necas et al. 2008). To
survive, cancer cells must have the ability to adhere to the matrix
(Delpech et al. 1997). Tumor cells contain HA, which induces cell
growth, migration, and the ability to metastasize (Misra et al. 2015).
HA is produced by enzymes called hyaluronan synthases and is degraded by enzymes called hyaluronidases (Kultii et al. 2012).
HA protects tumors from attacks from the immune system
(Misra et al. 2015). Focusing on the mechanism and cell receptors
that aid the relationship between HA and tumor growth could be the
key to defining new treatment methods for cancer. By disrupting
the protective environment of the tumor cell, the effectiveness of
the anti-cancer properties of the CDT may be enhanced. Evans et

Figure 5. The chemical structure of Hyaluronan (Necas et al. 2008).

al. (2017) tested and compared the efficiency of CDT analogues in
the presence of hyaluronidase, which degrades HA and chondroitin sulfate. As discussed above, chondroitin sulfate inhibits cationic
peptide activity (Fadnes et al. 2009). D-CDT lost its activity when
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the cells were treated with hyaluronidase before the peptide, suggesting that HA somehow plays a role in the anti-cancer mechanism
of D-CDT. In all, the study ruled out apoptosis as a mechanism, unlike RGD-Tachyplesin used, but retained the dependence on the HA
interaction as a possibility (Evans et al. 2017).
The CD44 receptor is characterized by its interaction
with HA, along with other receptors such as LYVE-1, TLR-4, and
RHAMM (Matthaiolampakis et al. 2015; Litwinuik et al. 2016;
see Figure 6 below). The binding sequence B(X7)B is the HA
binding sequence, which allows peptides to interact with receptor
domains (Yang et al. 1994). B represents a basic amino acid, arginine or lysine, and X7 represents any other amino acid (Yang et al.
1994.). This binding sequence can be found within the sequence of
CDT (RVYRGIYRR). This is similar to the sequence that Wood et
al. (2014) found to be effective against bacteria but did not induce
hemolysis. The mechanism to kill cancer cells could therefore be
increased, due to the binding sequence of HA found in CDT interacting with receptors found on the membrane of the cancer cell.
Looking forward, testing the shorted internal part of CDT,
which only contains this binding sequence, against cancer cells in
both the natural L-form and D-form may exhibit increased activity
against A549 lung cancer cells. Shortening the sequence of the pep-

Figure 6. Receptors that interact with Hyaluronan (Litwinuik et al. 2016.)
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tide makes it more deliverable, less immunogenic, and both easier
and cheaper to synthesize. The D-form affords some protection from
natural proteases, which only recognize L-amino acids, and gives it a
longer half-life in addition to unique conformational properties.
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